Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
About the study
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
- Adequate bone marrow, kidney and liver function
- Performance status of 0 or 1.
- Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
EXCLUSION CRITERIA
Exclusion Criteria:
- Prior treatment targeting ILT3.
- Prior treatment targeting LAIR1.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Pancreatic Cancer,Breast Cancer,Gastric Cancer,Non-small Cell Lung Cancer,Cervical Cancer,Endocervical Cancer,Squamous Cell Carcinoma of Head and Neck,Bladder Urothelial Cancer,Colorectal Carcinoma,Esophageal Cancer,Ovarian Cancer,Renal Cell Carcinoma,Prostate Cancer,Melanoma,Mesothelioma,Cholangiocarcinoma
Age (in years)
18+
Phase
PHASE1
Participants needed
130
Est. Completion Date
Mar 31, 2026
Treatment type
INTERVENTIONAL
Sponsor
NGM Biopharmaceuticals, Inc
ClinicalTrials.gov identifier
NCT05215574
Study number
831-IO-101
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?